Utilising an interleukin-12 plasmid: a novel COVID-19 vaccine
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
List view / Grid view
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
Researchers in Boston have repurposed their lab into a centre to test samples for COVID-19, releasing a blueprint of how to do so for other labs in the US.
The COVID-19 Protein Portal, established by UKRI and Wellcome, will allow scientists in the UK to access protein reagents needed for research.
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
Russian researchers have created a process for the development of mouse models for use in pre-clinical studies of COVID-19 treatments and vaccines.
A new kind of dendritic cell has been discovered by researchers and could play a role presenting antigens to other immune cells during respiratory virus infections.
Researchers have found that molecules from ticks called Evasins have the potential to halt cytokine storms, the leading cause of COVID-19 fatalities.
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
Tested on plaque reducing assays, researchers have identified a lead candidate multivalent carbohydrate-binding module for the treatment of COVID-19.
Researchers have identified a structural loop in the SARS-CoV-2 S protein and a sequence of four amino acids that they say could help explain its high transmission rate.
After analysing the genomic diversity in SARS-CoV-2 by screening over 7,500 viruses from infected patients, researchers have offered clues for COVID-19 drug development.
Researchers have shown that the activation sequence the SARS-CoV-2 S protein is cleaved by the cellular enzyme furin which is also required for the infection of lung cells.
An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.
High-resolution mass spectrometry has been used by researchers to map the glycan-processing states of the Spike protein of the SARS-CoV-2 virus, which causes COVID-19.
Next-generation sequencing has revealed an 81-base pair mutation of the SARS-CoV-2 virus, which could be used to develop new antivirals or vaccines.